Chronic kidney disease (CKD) is a systemic condition that affects not only kidney function but virtually every organ system in the body. Skin changes significantly reduce the quality of life in these patients, and uremic pruritus represents one of the most frequently encountered and most challenging symptoms. Approximately 40 to 70 percent of dialysis patients suffer from severe itching.
Pathophysiology of Uremic Pruritus
The precise mechanism of uremic pruritus has not yet been fully elucidated; however, the interaction of multiple factors is involved. Accumulation of uremic toxins, calcium-phosphorus imbalance, secondary hyperparathyroidism, systemic inflammation, and peripheral neuropathy are all components of this complex picture.
The role of non-histamine pruritus mediators in the skin is becoming increasingly well understood. Substance P, interleukin-31, and opioid receptor imbalance play important roles in uremic pruritus. This knowledge has guided the development of treatment strategies.
Skin Manifestations in Kidney Failure
In addition to pruritus, CKD patients exhibit numerous dermatological findings. Skin dryness (xerosis) is the most common finding, observed in 50 to 85 percent of patients. The skin taking on a pale or yellowish-brown color is associated with the accumulation of urochrome pigment.
Half-and-half nails (Lindsay's nails) are characterized by whitening of the proximal nail bed and brownish discoloration of the distal portion. Furthermore, prurigo nodularis, lichenification, and excoriations frequently develop as a result of chronic scratching secondary to pruritus.
Calciphylaxis, related to calcification disorders, is a rare but life-threatening complication. Calcium deposition in subcutaneous blood vessels can lead to painful necrotic ulcers.
Current 2026 Treatment Approaches
Topical Treatments
Regular moisturizers form the cornerstone of uremic pruritus management. Ceramide-containing, fragrance-free, and hypoallergenic formulations should be preferred. Topical capsaicin cream can reduce pruritus through substance P depletion. Calcineurin inhibitors — tacrolimus and pimecrolimus — are effective particularly on localized pruritic areas.
Creams containing topical gamma-linolenic acid support skin barrier function, while lotions containing pramoxine hydrochloride exert a local anesthetic effect.
Systemic Treatments
Gabapentin and pregabalin are effective agents targeting the neuropathic component of pruritus. Dose adjustment in dialysis patients must be performed carefully. Opioid antagonists such as naltrexone can relieve pruritus by correcting opioid receptor imbalance.
In 2026, interleukin-31 receptor antagonists continue to show promising results in the treatment of uremic pruritus. Difelikefalin, a kappa opioid receptor agonist, significantly reduces pruritus in dialysis patients.
Phototherapy
Narrowband UVB phototherapy is an effective option for uremic pruritus that does not respond to topical treatments. Administered two to three sessions per week, treatment can provide marked improvement within an average of six to eight weeks.
Aesthetic Considerations and Important Precautions
When planning aesthetic procedures in CKD patients, it must be kept in mind that the skin's healing capacity is reduced. Transplant patients on immunosuppressive medications require particular attention regarding infection risk. Biocompatible and temporary materials should be preferred in dermal filler applications.
Holistic Patient Management
Success in treating uremic pruritus is achievable through coordination between nephrology and dermatology. Ensuring adequate dialysis, optimizing calcium-phosphorus balance, and controlling comorbid conditions directly influence treatment response. At Virtuana Clinic, skin care protocols tailored specifically for patients with kidney failure are implemented.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.